Adage Capital Partners Gp, L.L.C. Kymera Therapeutics, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $56.4 Billion
- Q2 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 304,200 shares of KYMR stock, worth $17.5 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
304,200Holding current value
$17.5 Million% of portfolio
0.02%Shares
7 transactions
Others Institutions Holding KYMR
# of Institutions
217Shares Held
72.2MCall Options Held
178KPut Options Held
64.6K-
Price T Rowe Associates Inc Baltimore, MD6.86MShares$395 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6.65MShares$383 Million2.94% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.56MShares$377 Million5.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.62MShares$323 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA5.5MShares$317 Million9.44% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $3.15B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...